Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jul 1;37(4):357-363.
doi: 10.1097/MOG.0000000000000740.

New targets in inflammatory bowel disease therapy: 2021

Nathaniel A Cohen  1 , David T Rubin
Affiliations
Review

New targets in inflammatory bowel disease therapy: 2021

Nathaniel A Cohen et al. Curr Opin Gastroenterol. .

Abstract

Purpose of review: In the rapidly progressing world of inflammatory bowel disease, this review discusses and summarizes new drug targets and results from major clinical trials in order to provide an update to physicians treating patients with inflammatory bowel diseases (IBD).

Recent findings: Multiple new mechanisms in the treatment of IBD are being developed and many are showing promising results in both ulcerative colitis and Crohn's disease patients. In addition to efficacy, some of these treatments may provide safety benefits over existing therapies.

Summary: The IBD physicians' therapeutic armamentarium is rapidly expanding and keeping abreast of these developments is required in order to provide patients with optimized individualized care.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Clinical trial pipeline of IBD therapies Outer ring: Phase 1, Middle ring: Phase 2, Inner circle: Phase 3
See this image and copyright information in PMC

References

    1. Habibi F, Habibi ME, Gharavinia A, Mahdavi SB, Akbarpour MJ, Baghaei A, et al. Quality of life in inflammatory bowel disease patients: A cross-sectional study. J Res Med Sci. 2017; - PMC - PubMed
    1. Peyrin-Biroulet L, Panés J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions. Clin Gastroenterol Hepatol. 2016; - PubMed
    1. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab Maintenance Therapy for Fistulizing Crohn’s Disease. N Engl J Med. 2004; - PubMed
    1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; - PubMed
    1. Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lulcas M, MacIntosh DG, et al. Adalimumab for maintenance treatment of Crohn’s disease: Results of the CLASSIC II trial. Gut. 2007; - PMC - PubMed

MeSH terms